RxDoctor Payments Data

Melissa Parks, NP

Nurse Practitioner · Dalton, GANPI 1114277324

Payments from drug & device makers

$8,304in general payments, 2019–2025

Across 450 payments — averaging $18.45 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • UCB, Inc.$921
  • AbbVie$877
  • MDD US Operations, LLC$554
  • Eisai Inc.$424
  • Bristol Myers Squibb$406
  • Amneal Pharmaceuticals LLC$387
  • plus $5K from 42 others

What the payments were for

  • Food & beverage$8,295100%
  • Education$90%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$8,304 in reported general payments places this provider in the 95th percentile of 3,328 nurse practitioner providers in Georgia.

See all nurse practitioner providers in Georgia

Medicare billing

Part B allowed, 2024
$82,485
Medicare patients
358
Services billed
916

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Austedo XrDeutetrabenazine16$146,536
BriviactBrivaracetam61$92,435
IngrezzaValbenazine Tosylate11$84,939
UbrelvyUbrogepant30$35,200
Nurtec OdtRimegepant Sulfate26$33,040
Aimovig AutoinjectorErenumab-Aooe32$22,870
XcopriCenobamate14$15,876
QuliptaAtogepant13$13,732
VimpatLacosamide12$13,206
TrintellixVortioxetine Hydrobromide13$6,407
Lacosamide42$5,436
Memantine Hcl193$4,027
Carbidopa-LevodopaCarbidopa/Levodopa101$2,375
Rivastigmine12$2,313
Lamotrigine ErLamotrigine11$2,143

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Teva Pharmaceuticals USA, Inc.Austedo Xr$94$146,53616 claims
UCB, Inc.Briviact, Vimpat$921$105,64073 claims
Neurocrine Biosciences, Inc.Ingrezza$175$84,93911 claims
AbbVieUbrelvy, Qulipta$877$48,93243 claims
PfizerNurtec Odt$289$33,04026 claims
SK Life Science, Inc.Xcopri$260$15,87614 claims
Amneal Pharmaceuticals LLCPyridostigmine Bromide$387$1,32112 claims
Upsher-smith Laboratories LLCTopiramate$16$682101 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 3,328 nurse practitioner providers in Georgia.

Other nurse practitioner in Dalton

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →